Perseus Proteomics, Inc.

As of March 31, 2026, Perseus Proteomics, Inc. carries a market capitalization of 3.74B, placing it among publicly traded companies globally. Its enterprise value stands at 2.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Perseus Proteomics, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, Perseus Proteomics, Inc. has 17.00M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Perseus Proteomics, Inc. maintains a current ratio of 24.58, meaning it holds 24.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Perseus Proteomics, Inc.'s stock has declined approximately 53.55% over the past 52 weeks. The 50-day moving average sits at 154.80, while the 200-day moving average is 190.47.

These figures are as of March 31, 2026. Total book value stands at 1.22B, with working capital of 1.54B providing operational flexibility.